Publications by authors named "Andre Maroccolo de Sousa"
Paclitaxel-Coated Balloon for the Management of In-Stent Coronary Restenosis: An Updated Meta-Analysis and Trial Sequential Analysis.
Catheter Cardiovasc Interv
January 2025
Background: Drug-coated balloons present a potentially advantageous therapeutic approach for managing coronary in-stent restenosis (ISR). However, the comparative benefits of paclitaxel-coated balloons (PCBs) over uncoated balloons (UCBs) remain unclear.
Aims: We conducted a systematic review and meta-analysis to evaluate and compare the clinical outcomes of patients treated with PCBs and UCBs.
Subcutaneous versus transvenous implantable cardioverter defibrillator in hypertrophic cardiomyopathy: a systematic review and meta-analysis.
Cardiovasc Diagn Ther
June 2024
Background: A subcutaneous implantable cardioverter-defibrillator (S-ICD) is an alternative to a transvenous implantable cardio defibrillator (TV-ICD). An S-ICD reduces the risk of transvenous lead placement. However, further research is required to determine how S-ICDs affect patients with hypertrophic cardiomyopathy (HCM).
View Article and Find Full Text PDFArticle Synopsis
- Leadless pacemakers (LPs) show promise as safer alternatives to traditional transvenous pacemakers (TVPs), with significantly lower overall complication rates, including issues like dislodgement and pneumothorax.
- While LPs do not show a significant difference in all-cause mortality compared to TVPs, they come with a higher risk of pericardial effusion and cardiac tamponade.
- The study emphasizes the need for randomized controlled trials to further validate the comparative effectiveness and safety of LPs versus TVPs.
Saroglitazar is a novel medication for dyslipidemia, but its specific effects remain unclear. Therefore, we performed a systematic review and meta-analysis to assess the efficacy and safety of saroglitazar for managing dyslipidemia. The PubMed, Scopus, and EMBASE databases were systematically searched for randomized controlled trials (RCTs) comparing 2 and 4 mg of saroglitazar with placebos for treating dyslipidemia.
View Article and Find Full Text PDF